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Background. The majority of people at ultra high risk (UHR) of psychosis also present with co-morbid affective
disorders such as depression or anxiety. The neuroanatomical and clinical impact of UHR co-morbidity is unknown.
Method. We investigated group differences in grey matter volume using baseline magnetic resonance images from 121
participants in four groups: UHR with depressive or anxiety co-morbidity; UHR alone; major depressive disorder; and
healthy controls. The impact of grey matter volume on baseline and longitudinal clinical/functional data was assessed
with regression analyses.
Results. The UHR-co-morbidity group had lower grey matter volume in the anterior cingulate cortex than the
UHR-alone group, with an intermediate effect between controls and patients with major depressive disorder. In
the UHR-co-morbidity group, baseline anterior cingulate volume was negatively correlated with baseline suicidality/
self-harm and obsessive–compulsive disorder symptoms.
Conclusions. Co-morbid depression and anxiety disorders contributed distinctive grey matter volume reductions of the
anterior cingulate cortex in people at UHR of psychosis. These volumetric deficits were correlated with baseline measures
of depression and anxiety, suggesting that co-morbid depressive and anxiety diagnoses should be carefully considered in
future clinical and imaging studies of the psychosis high-risk state.
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Introduction
Affective disorders are prevalent concomitants of the
ultra high risk (UHR) of psychosis (Fusar-Poli et al.
2013a). Symptoms of depression and anxiety are
often the primary presenting complaint of the UHR
patient rather than the attenuated psychotic symp-
toms, with a significant impact on psychosocial and
emotional functioning (Fusar-Poli et al. 2013a). A recent
study in about 500 UHR individuals reported a 73%
prevalence of baseline co-morbid Axis I diagnoses,
mostly depressive disorders, in addition to the attenu-
ated psychotic symptoms (Fusar-Poli et al. 2014b). De-
pressive and anxiety symptoms may chronologically
predate the onset of attenuated psychotic symptoms
(Fusar-Poli et al. 2013a), reflecting core psychopatho-
logical features during the prodromal phases of psy-
chosis (Mishara & Fusar-Poli, 2013). Such symptoms
pose challenges in the clinical management of those
who attend high-risk services (Fusar-Poli et al. 2013a),
and make a negative impact on the longitudinal prog-
nosis of those who meet criteria for UHR for psychosis
(Demjaha et al. 2012; Salokangas et al. 2012). However,
the contribution of affective symptoms to UHR neuro-
biology remains unknown.
Depressive and anxiety disorders have specific neuro-
anatomical, neurofunctional and neurochemical fea-
tures (Radua et al. 2010; Sacher et al. 2012); therefore
the high prevalence of these symptoms in UHR cohorts
could potentially confound previous neurobiological
findings in these subjects. Consequently, this hetero-
geneity across individual neuroimaging studies (Fusar-
Poli et al. 2011, 2012) may prevent the identification of
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reliable markers of psychosis risk. The lack of
specificity regarding the neurobiological correlates
of UHR states (Fusar-Poli et al. 2014c) may ultimately
affect the validity of the paradigm itself and prevent
further developments in the field. A recent consensus
paper indicated that the lack of studies testing the val-
idity of the UHR paradigm against other psychiatric
samples (such as those affected by depressive dis-
orders) prevented its final inclusion in the recent Diag-
nostic and Statistical Manual of Mental Disorders,
fifth edition (DSM-5) (Yung et al. 2012). Furthermore,
criterion E of the proposed ‘attenuated psychosis
syndrome’ requires that symptoms are not better ex-
plained by any other DSM diagnosis (Tsuang et al.
2013). Consequently, the question of the clinical and
neuroanatomical specificity of UHR symptoms as op-
posed to depressive or anxiety symptoms is of crucial
nosographic relevance (van Os & Murray, 2013).
To date, imaging studies have assumed that UHR
states are characterized by common neuroanatomical
alterations. However, this seems unlikely given the
wide range of symptomatic co-morbidities that are
present in UHR cohorts and the heterogeneity of clini-
cal outcomes. Human in vivo neuroimaging studies
have shown that UHR states and affective disorders
such as major depressive disorder (MDD) each have
distinct deleterious effects on the brain and associated
cognitive and social behaviour (Fusar-Poli et al.
2011; Bora et al. 2012). In MDD, imaging studies
report grey matter volume (GMV) reductions most
robustly in the rostral anterior cingulate cortex (ACC)
(Drevets, 2000, 2001; Bora et al. 2012; Sacher et al.
2012). In UHR cohorts, quantitative brain imaging
studies report substantial GMV deficits compared
with healthy controls, most consistently found in the
temporal and frontal cortices, the limbic system and
the cerebellum (Pantelis et al. 2003; Borgwardt et al.
2007; Meisenzahl et al. 2008). To our knowledge, the
neuroanatomical impact of these UHR co-morbidities
has never been studied.
Here we tested the hypothesis that co-morbid de-
pressive and anxiety disorders make an impact upon
the neuroanatomy of psychosis risk. In the light of
the high co-morbid prevalence of these disorders,
we examined their contribution to grey-matter UHR
abnormalities using a whole-brain voxel-based mor-
phometry method (VBM). We included 121 men and
women from four groups: (1) UHR alone; (2) UHR
with anxiety or depressive co-morbidity; (3) healthy
controls (HC); and (4) MDD alone. The latter group
was selected to test the validity (Tsuang et al. 2013)
and specificity (Yung et al. 2012) of UHR neuroanat-
omy in comparison with other psychiatric diagnoses.
Our first hypothesis was that the UHR group as a
whole would show GMV decreases relative to HCs
in line with previous findings (Fusar-Poli et al. 2011),
but that stratifying the sample on the basis of co-
morbidity would reveal different patterns of GMV
change, particularly in the ACC (Bora et al. 2012).
Given the higher prevalence of attenuated depressive
symptoms in the UHR group compared with HCs
(Fusar-Poli et al. 2014b), we specifically hypothesized
that the UHR co-morbidity group would show an
intermediate pattern of ACC grey-matter change
between MDD and UHR-alone patients. Second, we
hypothesized that neuroanatomical alterations in
UHR subjects with co-morbidity would be correlated
with baseline and longitudinal clinical and functional




Individuals meeting Personal Assessment and Crisis
Evaluation (Yung et al. 1998) criteria for an at-risk
mental state for psychosis (UHR) were recruited
from a prodromal clinical service, the Outreach and
Support in South London service (OASIS) (Fusar-Poli
et al. 2013b). Details of these criteria are appended in
the online Supplementary Method.
The total sample consisted of 52 UHR subjects
(mean age=25.3 years, S.D.=4.3 years, 62% males),
whose individual structural magnetic resonance imag-
ing (MRI) scans were collected at baseline from con-
secutive referrals to OASIS (Broome et al. 2005). All
UHR participants were antipsychotic naive at the
time of scanning. The UHR group was divided accord-
ing to depression and anxiety co-morbidity (‘UHR
co-morbidity’: n=32, mean age=23.6 years, S.D. =
4.2 years, 69% males; ‘UHR alone’: n=20, mean age=
23.3 years, S.D.=4.8 years, 60% males), in line with
our previous behavioural multicentre study (Fusar-
Poli et al. 2014b). Current DSM diagnoses of Axis I
co-morbidity (anxiety, depression, and anxiety plus
depression disorders) were assessed during the initial
assessment at the OASIS clinic using the Structured
Clinical Interview for DSM-IV (SCID) (First et al.
1996). All UHR subjects were followed up clinically
(for at least 2 years). Clinical (transition to psychosis)
and functional (good/poor) outcomes were determined
with the Comprehensive Assessment of At Risk Mental
States (CAARMS; Yung et al. 2005) and Global Assess-
ment of Functioning (GAF) (APA, 1994), respectively,
while the sociodemographic characteristics were
recorded through unstandardized and locally devel-
oped questionnaires (Schennach-Wolff et al. 2009).
We accessed information on the treatments that had
been offered to UHR subjects during their clinical
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management at the OASIS clinic (i.e. from baseline to
follow-up) from the OASIS patient records. Therefore,
the clinical assessment was carried out at two time
points (baseline and follow-up), and the MRI was
only carried out at baseline.
MDD group
A total of 23 individuals with MDD (mean age=44.6
years, S.D.=5.5 years, 13% males) were recruited from
services at the South London and Maudsley National
Health Service Trust. MDD was assessed with the
SCID (First et al. 1996), and diagnosed using DSM-IV
criteria (APA, 1994), by the psychiatrist responsible
for the patients’ management at the Maudsley Hos-
pital, London. Ethical approval was obtained from
the Ethical Committee of the South London and
Maudsley Trust and Institute of Psychiatry. Written
consent was obtained from all subjects prior to par-
ticipation in the study. Exclusion criteria included a
history of head injury, illicit substance abuse, and
a score of less than 24 on the Mini-Mental State Exam-
ination (Folstein et al. 1975).
HC group
A total of 46 healthy volunteers (mean age=25.3 years,
S.D. =4.3 years, 69% males) were recruited via adver-
tisements in the local media. All individuals lived in
the same borough of London as the clinical par-
ticipants (Lambeth/Southwark). The HC sample was
comparable with the total UHR group for gender
and age.
For all participants, exclusion criteria included other
past/present diagnosis of Axis I psychiatric illnesses,
past/present/familiar history of neurological illness,
intellectual impairments, medical illness, alcohol or
other substance abuse or dependence (defined using
DSM-IV criteria), and pregnancy.
MRI acquisition
MR images were acquired using a GE Signa 1.5 T MR
system (General Electric, USA) at the Maudsley Hos-
pital, London. Subjects were scanned with a T1-
weighted three-dimensional spoiled gradient recall
sequence with 1.5mm thickness and 0 gap (repetition
time=3000ms, inversion time=300ms, echo time=
40ms), producing 124 slices.
Data analysis
Sociodemographic, clinical and functional data
Differences in demographic, clinical and functional
characteristics between groups at baseline and follow-
up cross-sectionally were examined using one-way
analysis of variance for parametric data and a χ2 test
for non-parametric data. The interaction between
CAARMS assessment time (baseline, follow-up) and
group (UHR alone, UHR co-morbidity) was tested
with a repeated-measures analysis of variance. All
analyses were performed using SPSS version 20.0 for
Mac (IBM, USA).
Image preprocessing
Structural images were preprocessed using VBM im-
plemented in the SPM8 software package (Wellcome
Department of Cognitive Neurology, UK) running
under Matlab 8.1 (The Mathworks, USA). Further
details on image pre-processing are appended in the
Supplementary Method.
Image analysis
To test our first hypothesis, an analysis of variance was
designed using SPM8 (http://www.fil.ion.ucl.ac.uk/
spm/software/spm8/) to compare the grey matter
images from participants with UHR co-morbidity,
MDD alone and UHR alone and HC participants. We
modelled age and gender as covariates of no interest
to identify regionally specific differences that were
not confounded by these variables. The proportional
scaling option was used to identify regional changes
that were not confounded by global differences in
GMV. Statistical inferences were made at p<0.05
family-wise error (FWE) across the whole brain, with
cluster-level correction as determined by the Monte
Carlo simulation program implemented in AlphaSim
(Song et al. 2011) (http://afni.nimh.nih.gov/pub/dist/
doc/manual/AlphaSim.pdf) (p=0.001, k=123). For the
comparison of UHR alone and UHR co-morbidity,
based on our a priori hypothesis of an effect in the
ACC derived from studies in MDD and in the early
phases of psychosis (Borgwardt et al. 2008; Bora et al.
2012; Radua et al. 2012; Sacher et al. 2012), we created
a pre-defined anatomical mask including the bilateral
ACC using Automated Anatomical Labeling as im-
plemented in the WFU_Pickatlas toolbox (including
2713 voxels). The extent threshold of the cluster for
this region-of-interest analysis (ROI) was also deter-
mined by Monte Carlo simulation (p=0.005, k=27) to
ensure an FWE correction level of p<0.05.
Baseline and longitudinal correlations of imaging data
with clinical and functional measures
To test our second prediction, correlations between
baseline ACC volume and baseline psychopathology
(CAARMS), as well as longitudinal CAARMS scores,
were tested using Pearson’s product–moment corre-
lation in SPSS (SPSS Inc., USA).
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In addition to the standard diagnostic subscales
of the CAARMS (unusual thought content, perceptual
abnormalities, speech disorders), we a priori focused
our correlational analyses on the avolition, disorgan-
ized behaviour, depression, suicidality/self-harm, an-
xiety and obsessive–compulsive disorder (OCD)
subscales of the CAARMS, since we previously
showed that co-morbid depressive and anxiety disor-
ders had a significant impact on these (Fusar-Poli
et al. 2014b). For completeness, we also analysed the
other psychopathological CAARMS domains, correct-
ing for multiple comparisons. Outliers were identified
with visual inspections of regression lines and the use
of Cook’s distance test. Predictions of transition and
functional outcomes (poor/good) of UHR individuals
based on ACC volume were conducted by using Cox
regression analyses and hazard ratios were estimated.
CAARMS subscales were treated as continuous vari-
ables consistent with prior research (e.g. Yung et al.
2005; Thompson et al. 2011; Valmaggia et al. 2013).
The poor and good functional outcome groups were
defined by a median split of scores, in line with pre-
vious studies in schizophrenia (Ho et al. 2003;
Spellmann et al. 2012; Wulff et al. 2012), and in UHR
individuals (Velthorst et al. 2013).
Results
Sociodemographic, clinical and functional data
There were no differences between the UHR-alone,
UHR-co-morbidity and HC groups in age or
gender. However, the MDD sample was significantly
older and had significantly more women (χ26=61.443,
p<0.001) than the other three groups (F3,120=120.944,
p<0.001; Bonferroni post-hoc correction was p<0.001
for MDD v. UHR alone, MDD v. UHR co-morbidity,
and MDD v. HC).
The clinical characteristics of the UHR subjects
(cross-sectionally and longitudinally) are detailed
in Table 1. Of the 52 UHR subjects, 32 (62%) had an
Axis I co-morbid diagnosis of depressive or anxiety
disorder in addition to the at-risk signs and symptoms.
Specifically, 26 out of 32 (81%) had a co-morbid diag-
nosis of depression alone or in association with anxiety
disorders. Anxiety disorders alone were less frequent,
found in six participants out of 32 (19%). UHR partici-
pants with and without co-morbidity did not differ on
interval between baseline and follow-up assessments.
The UHR groups differed at baseline on disorganized
speech (F1,47=4.202, p=0.046), with higher levels in
the UHR-co-morbidity group. The UHR-co-morbidity
group also had higher levels of avolition (F1,44=5.509,
p=0.023) and depression (F1,44=3.450, p=0.070, trend
level) (Table 1; see online Supplementary Table S1 for
the full baseline psychopathological assessment).
At follow-up, nine UHR individuals (17%) had de-
veloped psychosis, while the remaining 43 (83%) had
not. Average follow-up time was 5.5 (SD=2.9) years.
The UHR-alone and UHR-co-morbidity groups did
not differ in the number of transitions, or the pro-
portion of good and poor functional outcomes (GAF
median split =67.55). At follow-up, there were no sig-
nificant symptom differences between the UHR-alone
and UHR-co-morbidity groups (Table 1; see online
Supplementary Table S1 for the full follow-up psycho-
pathological assessment). However, there was a time×
group interaction, with an association between UHR
co-morbidity and larger improvements in depression
levels (F1,33 =4.699, p=0.037) over time compared
with UHR alone. Of note, there were significant differ-
ences in the treatments offered to the two groups
during their clinical management at the OASIS clinic
(i.e. from baseline to follow-up). The UHR-co-
morbidity individuals were more likely to be treated
with antipsychotics (χ21=5.953, p=0.015) and anti-
depressants (χ21=5.215, p=0.022), and less likely to be
treated with cognitive psychological therapies without
adjunctive medications (χ22=13.939, p=0.001) than the
UHR-alone group (Table 1).
Impact of depressive and anxiety co-morbid
disorder on UHR neuroanatomy
Patients with MDD showed GMV reductions, com-
pared with HC participants with a whole-brain ana-
lysis, in a large medial frontal cluster including the
orbital gyrus, ACC and medial frontal gyrus, as well
as in the middle temporal gyrus and the inferior
parietal lobe (online Supplementary Table S2 and
Fig. 1a). MDD patients also showed reductions in me-
dial frontal and inferior parietal clusters compared
with UHR-co-morbidity individuals (Fig. 1b), and simi-
larly with UHR-alone subjects (Fig. 1c).
There were GMV reductions in UHR-co-morbidity
compared with UHR-alone subjects as revealed by a
whole-brain analysis in the medial frontal gyrus and
the fusiform gyrus (online Supplementary Table S2).
The ROI analysis based on an anatomical ACC
mask showed a significant reduction in GMV in the
UHR-co-morbidity group relative to the UHR-alone
group in a cluster comprising the subgenual prefrontal
cortex and the pregenual ACC (online Supplementary
Table S2 and Fig. 2). Further analysis confirmed a trend
across the four groups, with MDD patients showing
the most pronounced decreases relative to HCs,
followed by the UHR-co-morbidity and UHR-alone
groups (main effect of group: F3,120=15.422, p<0.001;
Bonferroni post-hoc comparisons: MDD<HC, p<0.001;
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group (n=32) F or χ2 p
Baseline
Disorder of thought content 3.4 (1.4) 3.7 (1.5) 3.3 (1.3) 1.288 0.262
Perceptual abnormalities 2.5 (1.9) 2.7 (2.1) 2.5 (1.8) 0.144 0.706
Disorganized speech 1.5 (1.4) 1.0 (1.1) 1.8 (1.4) 4.202 0.046
Avolition 2.6 (1.7) 1.8 (1.7) 3.0 (1.6) 5.509 0.023
Disorganized behaviour 1.0 (1.3) 1.1 (1.2) 0.7 (1.3) 1.032 0.315
Depression 2.5 (1.8) 1.9 (1.5) 2.9 (1.8) 3.450 0.070
Suicidality 1.8 (1.6) 1.9 (1.8) 1.7 (1.5) 0.104 0.749
Anxiety 3.2 (1.6) 3.2 (1.6) 3.3 (1.6) 0.041 0.841
OCD 1.4 (1.5) 1.1 (1.3) 1.6 (1.5) 1.289 0.262
GAF, good 68.7 (8.4) 67.2 (7.2) 69.4 (9.1) 0.410 0.528
GAF, poor 50.0 (6.0) 50.3 (7.5) 49.9 (5.4) 0.021 0.887
Longitudinal follow-up
Disorder of thought content 1.7 (1.9) 1.7 (1.9) 1.8 (1.7) 0.017 0.898
Perceptual abnormalities 2.8 (1.8) 2.0 (1.8) 1.5 (1.8) 0.647 0.427
Disorganized speech 1.6 (1.4) 1.2 (1.6) 1.1 (1.4) 0.116 0.735
Avolition 2.6 (1.8) 1.0 (1.3) 1.3 (1.5) 0.271 0.606
Disorganized behaviour 1.3 (1.5) 0.1 (0.5) 0.3 (0.9) 0.192 0.664
Depression 2.8 (1.8) 1.2 (1.7) 1.5 (1.8) 0.370 0.547
Suicidality/self-harm 2.1 (1.5) 0.6 (1.1) 0.7 (1.1) 0.109 0.743
Anxiety 3.4 (1.5) 1.1 (1.6) 1.4 (1.6) 0.141 0.710
OCD 1.7 (1.5) 0.6 (1.2) 0.7 (1.3) 0.053 0.820
GAF, good 80.9 (8.4) 79.4 (7.8) 81.9 (9.1) 0.429 0.520
GAF, poor 52.8 (9.0) 47.8 (3.8) 54.6 (9.7) 2.288 0.149
Focused interventions, n (%)b
CBT only 17 (37.0) 12 (66.7) 5 (17.9)
Combinationc 28 (60.9) 5 (27.8) 23 (82.1) 13.939 0.001
Monitoring only 1 (2.2) 1 (5.6) 0
Antidepressants, n (%)b,d
Yes 14 (30.4) 2 (11.1) 12 (42.9) 5.215 0.022
No 32 (69.6) 16 (88.9) 16 (57.1)
Antipsychotics, n (%)e,f
Yes 21 (44.7) 4 (22.2) 17 (58.6) 5.953 0.015
No 26 (55.3) 14 (77.8) 12 (41.4)
Follow-up time, years 5.5 (2.9) 5.8 (2.5) 5.3 (3.1) 0.414 0.523
Transitions, n (%) 9 (17.3) 3 (15.0) 6 (18.8) 0.014 0.617
CAARMS, Comprehensive Assessment of the At-Risk Mental State; GAF, Global Assessment of Functioning; UHR,
ultra high risk of psychosis; OCD, obsessive–compulsive disorder; CBT, cognitive–behavioural therapy; OASIS, Outreach and
Support in South London service.
Data are given as mean (standard deviation) unless otherwise indicated.
a For the whole CAARMS subscales, see online Supplementary Tables S2 and S3.
b Reliable information on focused interventions and antidepressant medication was missing from six UHR participants
(two UHR alone+ four UHR co-morbidity).
c Combination of CBT and medication (antidepressants or antipsychotics).
d Antidepressants: exposure to any antidepressant at any point from OASIS intake until discharge from the service.
e Reliable information on antipsychotic medication was missing from five UHR participants (two UHR alone+ three UHR
co-morbidity).
f Antipsychotics: exposure to any antipsychotic at any point from OASIS intake until discharge from the service.
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MDD<UHR co-morbidity, p<0.001; MDD<UHR
alone, p<0.001; UHR co-morbidity<HC, p=0.027;
UHR co-morbidity<UHR alone, p=0.046; and HC<
UHR alone, p=0.827). We found no effect of age
(F1,120=1.355, p=0.247) or gender (F1,120 <1, N.S.) in the
analyses.
The results of the comparisons between UHR
(combined) versus HC, UHR alone versus HC and
UHR co-morbidity versusHC are reported in the online
Supplementary Results, and displayed in online Sup-
plementary Fig. S1 a–c.
Baseline and longitudinal correlations of ACC
volume with clinical and functional measures
In UHR-co-morbidity participants, and using a priori
CAARMS subscales on the basis of previous meta-
analytical results (Fusar-Poli et al. 2014b), ACC volume
was negatively correlated with baseline suicidality/
self-harm (r=–0.454, p=0.013) and OCD symptoms
(r=–0.386, p=0.039). Cook’s D test was applied to
rule out the influence of potential outliers. This correc-
tion strengthened the significance of the correlations in
both cases (suicidality/self-harm: r=–0.494, p=0.009;
OCD symptoms: r=–0.628, p<0.001) (Fig. 3). There
were no correlations at baseline or follow-up for either
the UHR-alone group or the UHR groups combined.
ACC volume did not predict clinical transition or
functional outcomes in either UHR subgroup (see
online Supplementary Table S3). However, as noted
above, this group was receiving more intensive treat-
ments than the UHR-alone group over the duration
of the study.
For completeness, we tested in a collateral analysis
whether the above findings survived after removing
UHR subjects with anxiety alone from the UHR-
co-morbidity group. Full results are presented in the
online Supplementary Results.
Discussion
To our knowledge, this is the first study to examine the
impact of depressive and anxiety co-morbidity on the
neuroanatomy of subjects at UHR of psychosis.
Based on previous MRI studies of UHR samples
(Wood et al. 2008; Fusar-Poli et al. 2011; Mechelli
et al. 2011), our first hypothesis was that the UHR
group as a whole would show GMV decreases relative
to HCs, but that stratifying the sample on the basis
of co-morbidity would reveal different patterns of
GMV change. In line with a recent meta-analysis
(Fusar-Poli et al. 2011), UHR individuals as a whole
showed decreased GMV in frontal regions, including
the rolandic operculum, inferior frontal gyrus, medial
frontal gyrus and orbitofrontal gyrus. However,
when they were clinically stratified according to the
presence or absence of depressive and anxiety co-
morbidity, the co-morbid group showed further re-
ductions in a temporal region. Furthermore, the
direct comparison between UHR-co-morbidity and
UHR-alone participants at the whole-brain level
showed a significant reduction in UHR-co-morbidity
participants in the medial frontal gyrus and the
fusiform gyrus. In addition, the ROI analysis on this
comparison showed a significant reduction in UHR
individuals with co-morbid depressive and anxiety
disorders in the hypothesized ACC region. As hypoth-
esized, UHR-co-morbidity individuals showed an
intermediate effect between patients with MDD alone
(who showed the most pronounced decreases in
this region) and UHR alone, suggesting that GMV
decreases in the ACC are associated with an increased
severity of depressive symptomatology. Future studies
incorporating measures of severity of depressive sym-
ptoms in an MDD group may help expand this finding.
The ACC region implicated in our study comprised
the subgenual prefrontal cortex and pregenual ACC.
Prior evidence on the neuroanatomical basis of de-
pressive symptomatology has typically highlighted
ACC abnormalities as one of the most robust character-
istics of the pathophysiology of MDD (Drevets, 2001;
Bora et al. 2012; Sacher et al. 2012). Grey matter abnor-




Fig. 1. Group differences in grey matter volume. Differences
between healthy control (HC) participants and major
depressive disorder (MDD) patients (a), between patients at
ultra high risk (UHR) of psychosis alone and MDD patients
(b), and between UHR patients with depressive or anxiety
co-morbidity and MDD patients (c) (p<0.05 after
family-wise error correction).
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UHR samples regardless of their co-morbidity status
(Borgwardt et al. 2008; Fornito et al. 2008; Fusar-Poli
et al. 2011; Radua et al. 2012). The detection of ab-
normalities in this region, which were more severe in
the UHR-co-morbidity group, suggests a dysfunction
within the limbic portions of the ACC that are
known to modulate subcortical limbic and brainstem
structures that mediate emotional and social behaviour
(Damasio et al. 1990). This dysfunction may be key
to the pathogenesis of depressive and anxiety co-
morbidity in UHR subjects. Histopathological studies
in MDD have revealed specific morphometric changes
in the frontal cortex including the ACC (Rajkowska
et al. 1999) that are hypothesized to be due to glial
pathology and suggest that such neuroplastic changes
could cause a potential dysregulation in the fronto-
limbic circuit involved in the pathology of depression
(Schroeter et al. 2008, 2010). Although largely spec-
ulative due to the absence of histopathological evi-
dence from individuals at UHR of psychosis, one
possibility for the observed neuroanatomical changes
in UHR-co-morbidity subjects would be that they orig-
inate as suggested by the histopathologically generated
hypothesis of glial pathology in depression, and
accompany the morphometric changes typically as-
sociated with the UHR. Evidence from a range of
methodologies including neuroimaging, lesion ana-
lysis and electrophysiological studies of humans and
experimental animals all show that reduction in ACC
volume and histopathological changes in this area
can modulate emotional behaviour and stress re-
sponses (Drevets, 2000, 2001). Human lesion studies
of the ventral ACC have documented abnormal auto-
nomic responses to emotionally provocative stimuli,
decreased emotional experience, and an impact on so-
cial behaviour by causing inability to use information
regarding the probability of aversive social conse-
quences versus reward in guiding social behaviour
(Damasio et al. 1990). Our results tentatively suggest
a neural model of depressive and anxiety co-morbidity
in UHR subjects in which neuroanatomical changes in
the ACC increase the severity of affective symptoma-
tology. Correlation analysis between the positive sub-
scales and the depression and anxiety subscales of
the CAARMS yielded no significant associations in
the UHR group as a whole, or in the UHR subgroups,
providing further support for the idea that neuroanato-
mical changes in the UHR-co-morbidity group were
not simply due to a higher severity of overall psycho-
pathology. Nevertheless, as the first neuroanatomical
evidence of this kind, this finding needs to be repli-
cated in larger samples.
To test our second hypothesis, all UHR participants
were followed clinically subsequent to scanning to ex-
plore the impact of GMV alterations at baseline
on symptoms and functioning. Within the UHR-
co-morbidity group, ACC volume was negatively cor-
related with the baseline suicidality/self-harm and
Fig. 2. Effect of co-morbid depression and anxiety on anterior cingulate volume. Differences between ultra-high-risk (UHR)
individuals with (UHR co-morbidity) and without (UHR alone) depressive or anxiety co-morbidity, with a region-of-interest
approach on the anterior cingulate gyrus (p<0.05 after family-wise error correction). UHR-co-morbidity had less grey matter
volume in the anterior cingulate cortex [MNI (Montreal Neurological Institute) coordinates x, y and z: −8, 27 and −9,
respectively]. For visualization purposes, effects are displayed at p<0.05 uncorrected. The plot shows mean grey matter
volumes for the four groups derived from the main effect of group results; values on the y-axis refer to mm3 per voxel. HC,
Healthy control; MDD, major depressive disorder.
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OCD subscales of the CAARMS (showing less volume
with increased suicidality and OCD symptoms).
The neurobiological association of ACC with suicidal
behaviour has been widely supported by neuropatho-
logical studies (Hercher et al. 2010; Torres-Platas et al.
2011), studies in subjects at high risk for suicide
(Wagner et al. 2012) and studies in patients with
previous suicide attempts (Wagner et al. 2011; Pan
et al. 2013). These findings were detected in the con-
text of an overall clinical improvement of the UHR-
co-morbidity subgroup, as indicated by the longitu-
dinal increase in functional levels and by the lack of
significant between-group differences in psychopath-
ology at follow-up. These outcomes could be due to
spontaneous remission of the co-morbid symptoms,
or alternatively to the more intensive treatments
offered to these subjects during their clinical man-
agement. In fact, the presence of UHR co-morbidity
significantly made an impact on the clinical manage-
ment of UHR subjects during the duration of the
study. To the best of our knowledge this is the first
report showing that UHR patients with co-morbid de-
pressive or anxiety diagnoses tend to be treated with
more medications (antipsychotics and antidepressants)
and fewer psychological interventions as stand-alone
as compared with the UHR-alone group. Given that
antipsychotics and antidepressants in addition to psy-
chological interventions can prevent the onset of psy-
chosis (Fusar-Poli et al. 2007), the longitudinal results
of our cohort do not represent the natural history of
the UHR state. Furthermore, treatments for the UHR
state are commonly non-specific and may target de-
pression and anxiety and not only attenuated symp-
toms (O’Connor et al. 2007). This model is further
supported by recent meta-analytical evidence indicat-
ing that ACC structure is particularly sensitive to
antipsychotic treatment during the early phases of
psychosis (Radua et al. 2012). Additional functional
imaging evidence shows that a few weeks of antipsy-
chotic treatment can modulate the ACC response
(Lahti et al. 2004; Snitz et al. 2005). Overall, our results
support the notion that the UHR state should be
considered as a heterogeneous condition in which indi-
viduals present with a combination of psychotic and
affective (depression, anxiety) symptoms, some of
whom, but not all, have a true vulnerability to schizo-
phrenia (Fusar-Poli et al. 2014c). This is discussed in
more detail in two recent and comprehensive reviews
(Fusar-Poli et al. 2013a, 2014a). The present study pro-
vides additional evidence for this idea and demon-
strates at a neurobiological level the existence of a
depressive-anxiety UHR subtype that is characterized
by unique neuroanatomical characteristics along with
distinctive psychopathological, therapeutic and prog-
nostic features.
There are some limitations to the present study.
First, we lacked an additional group of patients affec-
ted with anxiety disorders only. This would have
allowed us to better delineate the neuroanatomical
circuits associated with depressive versus anxiety dis-
orders. Second, because our UHR-co-morbidity sample
was receiving distinctive preventative treatments as
compared with the UHR-alone group, the natural his-
tory of this subgroup could not be fully assessed. Fur-
thermore, we lacked a follow-up scan to clarify the
dynamic longitudinal course of the neuroanatomical
alterations observed in our UHR-co-morbidity group.
Third, the MDD group was older and the proportion
of females was higher compared with the UHR and
(a)
(b)
Fig. 3. Correlations between anterior cingulate cortex (ACC)
volume and baseline clinical profiles determined using the
Comprehensive Assessment of the At-Risk Mental State
(CAARMS) in patients at high risk of psychosis with
co-morbidity diagnoses. The plots show a significant
negative correlation between the grey matter volumes in the
ACC and baseline levels of CAARMS suicidality/self-harm
symptoms (a) and obsessive–compulsive disorder (OCD)
symptoms (b) (higher CAARMS values indicate higher
severity of symptoms).
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HC groups. Although we modelled these factors as
covariates of no interest in GMV analysis, a potential
confounding effect cannot be entirely ruled out. Future
studies with larger samples are needed to replicate our
findings. Information regarding the treatment of UHR
subjects during their clinical management at the OASIS
clinic (i.e. from baseline to follow-up) was obtained
from OASIS patient records.
In summary, our results suggest that depressive
and anxiety co-morbidity contributes to specific
GMV reductions in UHR subjects, primarily focused
in the pregenual ACC. This highlights the neurobiolo-
gical heterogeneity of UHR, which makes an impact
on clinical profiles of UHR individuals both cross-
sectionally on their clinical management and longitudi-
nal outcomes. Since co-morbid depressive and anxiety
diagnoses confer unique psychopathological, neuro-
anatomical, treatment and prognostic features to
UHR individuals, they should be carefully considered
in future imaging studies.
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